These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 16386100)

  • 1. Description and preliminary evaluation of a Multiagent Intelligent Dosing System (MAIDS) to manage combination insulin-oral agent therapy in type 2 diabetes.
    Cook CB; McMichael JP; Dunbar VG; Lieberman R
    Diabetes Technol Ther; 2005 Dec; 7(6):937-47. PubMed ID: 16386100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of insulin therapy in urban diabetes patients is facilitated by use of an intelligent dosing system.
    Cook CB; Mann LJ; King EC; New KM; Vaughn PS; Dames FD; Dunbar VG; Caudle JM; Tsui C; George CD; McMichael JP
    Diabetes Technol Ther; 2004 Jun; 6(3):326-35. PubMed ID: 15198835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simulation-Based Evaluation of Dose-Titration Algorithms for Rapid-Acting Insulin in Subjects with Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antihyperglycemic Medications.
    Ma X; Chien JY; Johnson J; Malone J; Sinha V
    Diabetes Technol Ther; 2017 Aug; 19(8):483-490. PubMed ID: 28700249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined pioglitazone and metformin treatment maintains the beneficial effect of short-term insulin infusion in patients with type 2 diabetes: results from a pilot study.
    Musholt PB; Schöndorf T; Pfützner A; Hohberg C; Kleine I; Fuchs W; Hehenwarter S; Dikta G; Kerschgens B; Forst T
    J Diabetes Sci Technol; 2009 Nov; 3(6):1442-50. PubMed ID: 20144400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin pump therapy in patients with type 2 diabetes safely improved glycemic control using a simple insulin dosing regimen.
    Edelman SV; Bode BW; Bailey TS; Kipnes MS; Brunelle R; Chen X; Frias JP
    Diabetes Technol Ther; 2010 Aug; 12(8):627-33. PubMed ID: 20615104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.
    Esposito K; Ciotola M; Maiorino MI; Gualdiero R; Schisano B; Ceriello A; Beneduce F; Feola G; Giugliano D
    Ann Intern Med; 2008 Oct; 149(8):531-9. PubMed ID: 18936501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous Glucose Monitoring and Insulin Informed Advisory System with Automated Titration and Dosing of Insulin Reduces Glucose Variability in Type 1 Diabetes Mellitus.
    Breton MD; Patek SD; Lv D; Schertz E; Robic J; Pinnata J; Kollar L; Barnett C; Wakeman C; Oliveri M; Fabris C; Chernavvsky D; Kovatchev BP; Anderson SM
    Diabetes Technol Ther; 2018 Aug; 20(8):531-540. PubMed ID: 29979618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin requirement profiles and related factors of insulin pump therapy in patients with type 2 diabetes.
    Yang X; Deng H; Zhang X; Yang D; Yan J; Yao B; Weng J; Xu W
    Sci China Life Sci; 2019 Nov; 62(11):1506-1513. PubMed ID: 31197759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous subcutaneous insulin infusion in patients with type 2 diabetes: a cohort study to establish the relationship between glucose control and plasma oxidized low density lipoprotein.
    Megson IL; Treweeke AT; Shaw A; MacRury SM; Setford S; Frias JP; Anhalt H
    J Diabetes Sci Technol; 2015 May; 9(3):573-80. PubMed ID: 25652563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Intelligent Dosing System: application for insulin therapy and diabetes management.
    Cook CB; McMichael JP; Lieberman R; Mann LJ; King EC; New KM; Vaughn PS; Dunbar VG; Caudle JM
    Diabetes Technol Ther; 2005 Feb; 7(1):58-71. PubMed ID: 15738704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
    Rosenstock J; Sugimoto D; Strange P; Stewart JA; Soltes-Rak E; Dailey G
    Diabetes Care; 2006 Mar; 29(3):554-9. PubMed ID: 16505505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: efficacy, safety, and cost analysis.
    Schwartz S; Sievers R; Strange P; Lyness WH; Hollander P;
    Diabetes Care; 2003 Aug; 26(8):2238-43. PubMed ID: 12882842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended-release formulation.
    Fujioka K; Pans M; Joyal S
    Clin Ther; 2003 Feb; 25(2):515-29. PubMed ID: 12749511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary, secondary, tertiary, and quaternary treatment with troglitazone in type 2 diabetes mellitus in an outpatient clinical practice.
    Hershon KS; Hershon PM
    Endocr Pract; 2000; 6(1):20-5. PubMed ID: 11419922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations between improved glucose control and patient-reported outcomes after initiation of insulin pump therapy in patients with type 2 diabetes mellitus.
    Peyrot M; Rubin RR; Chen X; Frias JP
    Diabetes Technol Ther; 2011 Apr; 13(4):471-6. PubMed ID: 21355725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: a randomized, open-label study.
    Ligthelm RJ; Gylvin T; DeLuzio T; Raskin P
    Endocr Pract; 2011; 17(1):41-50. PubMed ID: 20713345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapy.
    Hollander P; Sugimoto D; Vlajnic A; Kilo C
    J Diabetes Complications; 2015; 29(8):1266-71. PubMed ID: 26281972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycemic variability modifies the relationship between time in range and hemoglobin A1c estimated from continuous glucose monitoring: A preliminary study.
    Lu J; Ma X; Zhang L; Mo Y; Lu W; Zhu W; Bao Y; Jia W; Zhou J
    Diabetes Res Clin Pract; 2020 Mar; 161():108032. PubMed ID: 32006646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effect of Acarbose on Glycemic Variability in Patients with Type 2 Diabetes Mellitus Using Premixed Insulin Compared to Metformin (AIM): An Open-Label Randomized Trial.
    Gao F; Ma X; Peng J; Lu J; Lu W; Zhu W; Bao Y; Vigersky RA; Jia W; Zhou J
    Diabetes Technol Ther; 2020 Apr; 22(4):256-264. PubMed ID: 31638433
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.